Biktarvy Dosing for HIV-1
For most adults and adolescents with HIV-1, the standard dose of Biktarvy is one tablet containing 50 mg bictegravir, 200 mg emtricitabine, and 25 mg tenofovir alafenamide taken orally once daily, with or without food 1.
Standard Dosing by Weight and Age
Adults and Adolescents ≥25 kg
- One tablet (50/200/25 mg) once daily
- Requires estimated creatinine clearance (eCrCl) ≥30 mL/min 1
- Can be taken with or without food
Pediatric Patients 14 kg to <25 kg
- One tablet (30/120/15 mg) once daily
- Requires eCrCl ≥30 mL/min 1
- For children unable to swallow whole tablets, the tablet can be split and each part taken separately within approximately 10 minutes 1
Special Populations
Pregnant Individuals
Continue the standard 50/200/25 mg once daily dose in pregnant individuals who are virologically suppressed (HIV-1 RNA <50 copies/mL) 1. This applies only to those already on a stable antiretroviral regimen with no known resistance to Biktarvy components.
Critical caveat: Lower drug exposures occur during pregnancy, so viral load monitoring must be intensified 1. Current guidelines recommend Biktarvy during pregnancy with evidence rating BIIb, though dolutegravir-based regimens remain preferred (AIa rating) 2. Real-world data from 12 pregnant women showed good efficacy when adherence was maintained 3.
Hemodialysis Patients
For virologically-suppressed adults with end-stage renal disease (eCrCl <15 mL/min) on chronic hemodialysis:
- Standard 50/200/25 mg dose once daily
- Administer AFTER hemodialysis on dialysis days 1
Renal Impairment Contraindications
Do NOT use Biktarvy in 1:
- Severe renal impairment (eCrCl 15 to <30 mL/min)
- ESRD patients NOT on chronic hemodialysis
- Treatment-naïve ESRD patients on hemodialysis (only for virologically-suppressed patients)
Hepatic Impairment
Do NOT use in severe hepatic impairment (Child-Pugh Class C) 1. No dose adjustment needed for mild-to-moderate hepatic impairment.
Clinical Context and Guideline Support
Biktarvy (BIC/TAF/FTC) is recommended as a first-line regimen for most people with HIV by the 2024 IAS-USA guidelines with an AIa evidence rating 2. This places it among the highest-tier recommendations alongside dolutegravir-based regimens.
Key Advantages Supporting Once-Daily Dosing:
- High genetic barrier to resistance 4
- Minimal drug-drug interactions 5
- Single-tablet regimen enhancing adherence 6
- No boosting agents required 6
Treatment Populations
Treatment-Naïve Patients: Week 96 data from pivotal trials showed 88% virological suppression with excellent tolerability 7. Real-world Spanish cohorts confirmed these findings across diverse populations 5.
Treatment-Experienced/Virologically Suppressed: Switching to Biktarvy maintained suppression in 97.4-98% of patients at 6-12 months, even in those with multiple comorbidities and concomitant medications 8. This includes successful switches from rilpivirine-based regimens (98% suppression at 12 months) 8.
Second-Line Therapy: In Haiti, switching from ritonavir-boosted protease inhibitors to Biktarvy was non-inferior, with only 0.7% experiencing virological failure versus 4.1% continuing protease inhibitors 9.
Critical Monitoring Requirements
Before and during treatment, assess 1:
- Hepatitis B status (risk of severe exacerbation upon discontinuation)
- Serum creatinine and eCrCl
- Urine glucose and protein
- Serum phosphorus (if chronic kidney disease present)
Important Caveats
Resistance considerations: Do not use in patients with known resistance to bictegravir, emtricitabine, or tenofovir 1. For individuals who acquired HIV while on TAF/FTC or TDF/FTC PrEP, obtain genotyping before initiating therapy 2.
Hepatitis B co-infection: Biktarvy contains FTC and TAF, which have anti-HBV activity. Severe hepatitis B exacerbations can occur upon discontinuation—monitor hepatic function for several months after stopping 1.
Experimental dosing: Recent pilot data explored reduced-frequency dosing (twice or three times weekly), but protocol-defined virological failures occurred, and once-weekly dosing is not supported 10. Standard once-daily dosing remains the only validated approach.